Thyroid cancer: burden of illness and management of disease.
Thyroid cancer: burden of illness and management of disease.
复制标题
DOI：
10.7150/jca.2.193
复制
发表时间：
2011-04-04
影响因子：
3.9
通讯作者：
Cohen EE
中科院分区：
文献类型：
--
作者：
Brown RL;de Souza JA;Cohen EE
目的：甲状腺癌是最常见的内分泌恶性肿瘤，其发病率在过去五十年中急剧增加。本文将回顾甲状腺癌治疗的标准方法以及正在研究的新疗法。我们还将讨论甲状腺癌治疗中潜在的成本考虑因素。研究设计：进行了全面的文献检索。方法：复习文章。结果：甲状腺癌的高患病率和转移性疾病患者新疗法的可用性具有潜在的经济影响，但尚未得到充分研究。由于许多患者的癌症发病率可能非常低，因此需要更好的工具来识别风险最低的患者，以防止过度治疗。改进的风险分层应包括识别初次手术后不太可能从放射性碘治疗中受益的患者，以及识别不太可能从新疗法中受益的惰性和无症状转移性疾病的患者。对于患有晚期不治之症的患者，需要进行随机对照研究来评估新药的疗效，以确定与新药相关的成本是否合理。结论：与甲状腺癌诊断增加相关的医疗保健费用仍然未知，但值得进一步研究。
Objective: The incidence of thyroid cancer, the most common endocrine malignancy, has increased dramatically in the last fifty years. This article will review the standard approach to thyroid cancer treatment as well as novel therapies under investigation. We will also address potential cost considerations in the management of thyroid cancer. Study Design: A comprehensive literature search was performed. Methods: Review article. Results: The high prevalence of thyroid cancer and the availability of novel therapies for patients with metastatic disease have potential economic implications that have not been well-studied. Because many patients likely have very low morbidity from their cancers, better tools to identify the lowest risk patients are needed in order to prevent overtreatment. Improved risk stratification should include recognizing patients who are unlikely to benefit from radioactive iodine therapy after initial surgery and identifying those with indolent and asymptomatic metastatic disease that are unlikely to benefit from novel therapies. In patients with advanced incurable disease, randomized-controlled studies to assess the efficacy of novel agents are needed to determine if the costs associated with new agents are warranted. Conclusions: Health care costs associated with the increased diagnosis of thyroid cancer remain unknown but are worthy of further research.
登录
查看更多内容
DOI：
10.1200/jco.2007.15.9566
发表时间：
2008-10-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Cohen EE;Rosen LS;Vokes EE;Kies MS;Forastiere AA;Worden FP;Kane MA;Sherman E;Kim S;Bycott P;Tortorici M;Shalinsky DR;Liau KF;Cohen RB
通讯作者：
Cohen RB
影响因子：
5.9
作者：
MAZZAFERRI, EL;JHIANG, SM
通讯作者：
JHIANG, SM
影响因子：
2.6
作者：
DEGROOT, LJ;KAPLAN, EL;SHUKLA, MS
通讯作者：
SHUKLA, MS
影响因子：
6.6
作者：
Ain, Kenneth B.;Lee, Charles;Williams, Kevin D.
通讯作者：
Williams, Kevin D.
影响因子：
2.6
作者：
Hay, ID;Thompson, GB;Goellner, JR
通讯作者：
Goellner, JR